ARAF,BRAF,およびCRAF複合体の特徴と抑制剤の感受性
PubMedで要約を見る
まとめ
この要約は機械生成です。RAF阻害剤は,ARAF,BRAF,およびCRAFイソフォーム間で様々な有効性を示しています. タイプII阻害剤はCRAFに対して強力ですが,ARAFを省いて,がん治療の発達に影響します.
科学分野
- 腫瘍学
- 分子生物学
- 薬理学について
背景
- RAS-RAF-MEK-ERK経路は細胞成長を制御し,特にBRAF V600Eの変異はメラノーマのような癌を誘発する.
- ARAFとCRAFの活性化変異は,様々な癌でも発見されています.
- RAF阻害剤は重要ながん治療薬ですが,その同位体特異的な効能は体系的な比較を必要とします.
研究 の 目的
- 単体および二重体状態のRAFイソフォーム (ARAF,BRAF,CRAF) を生化学的に特徴付ける.
- 13種類のRAF阻害剤 (タイプI,I.5,II) の効能を3種類のRAF同型と比較する.
- RAF阻害剤の活性と選択性の構造的基礎を明らかにする.
主な方法
- 精製されたモノメリックおよび二重 ARAF,BRAF,およびCRAFの生化学的特徴.
- 阻害剤の効能 (IC50値) を決定するインビトロキナーゼアッセイ
- X線結晶学で,阻害剤を併用してCRAFの構造を決定する.
主要な成果
- タイプI阻害剤SB590885は,すべてのRAF同型体において同様の効能を示した.
- I. 5型阻害剤は,BRAF V600Eに対して最も強力でした.
- タイプII阻害剤はCRAFに対して強力で,ARAFを免れ,BRAFに対して中程度の効能を持ち,積極的な協力性を示した.
結論
- RAF阻害剤の有効性は異種によって著しく変化し,タイプII薬剤の"汎RAF阻害剤"分類に異議を唱える.
- 結晶構造は,阻害剤の結合時にRAFダイマーに独特の結合モードと形状の変化を明らかにする.
- この発見は,RAF阻害薬の微妙な理解を必要とし,より選択的で効果的ながん治療の開発を導く.
関連する概念動画
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Guanine nucleotide exchange factors or GEF,
GTPase-activating proteins or GAPs, and
Guanine nucleotide-dissociation inhibitors or GDIs.
The GEF activates the GTPase by exchanging the bound-GDP with GTP. The...
Rab proteins constitute the largest family of monomeric GTPases, of which 70 members are present in humans. Rab proteins and their effectors regulate consecutive stages of vesicle transport such as vesicle transport, docking, and fusion to the correct recipient membrane.
Rab proteins switch between a cytosolic, GDP-bound inactive state and a membrane-anchored, GTP-bound active state. By themselves, Rabs show slow rates of GDP/GTP exchange and GTP hydrolysis. Thus, Rab proteins are considered...

